• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Quantitative assessment of self-management in patients with non-alcoholic fatty liver disease: An unmet clinical need.非酒精性脂肪性肝病患者自我管理的定量评估:未满足的临床需求。
World J Gastroenterol. 2024 Jul 7;30(25):3143-3146. doi: 10.3748/wjg.v30.i25.3143.
2
Validation of adherence prediction system for lifestyle interventions in nonalcoholic fatty liver disease.非酒精性脂肪性肝病生活方式干预依从性预测系统的验证。
World J Gastroenterol. 2024 May 28;30(20):2629-2632. doi: 10.3748/wjg.v30.i20.2629.
3
Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease.建立和验证非酒精性脂肪性肝病生活方式干预依从性预测系统。
World J Gastroenterol. 2024 Mar 14;30(10):1393-1404. doi: 10.3748/wjg.v30.i10.1393.
4
Impact of lifestyle interventions on pathogenesis of nonalcoholic fatty liver disease.生活方式干预对非酒精性脂肪性肝病发病机制的影响。
World J Gastroenterol. 2024 May 28;30(20):2633-2637. doi: 10.3748/wjg.v30.i20.2633.
5
Scale offers the possibility of identifying adherence to lifestyle interventions in patients with non-alcoholic fatty liver disease.量表提供了识别非酒精性脂肪性肝病患者生活方式干预依从性的可能性。
World J Gastroenterol. 2024 Jul 7;30(25):3179-3181. doi: 10.3748/wjg.v30.i25.3179.
6
Management of non-alcoholic fatty liver disease: Lifestyle changes.非酒精性脂肪性肝病的管理:生活方式的改变。
World J Gastroenterol. 2024 Jun 14;30(22):2829-2833. doi: 10.3748/wjg.v30.i22.2829.
7
Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients.疾病认知和自我效能在非酒精性脂肪性肝病患者生活方式改变中的作用。
World J Gastroenterol. 2017 Mar 14;23(10):1881-1890. doi: 10.3748/wjg.v23.i10.1881.
8
Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.基于地中海生活方式的干预对非酒精性脂肪性肝病患者临床特征的改善:一项随机对照临床试验。
Br J Nutr. 2018 Jul;120(2):164-175. doi: 10.1017/S000711451800137X.
9
Lifestyle Modifications in Non-Alcoholic Fatty Liver Disease and Non- Alcoholic Steatohepatitis.非酒精性脂肪肝和非酒精性脂肪性肝炎的生活方式改变。
Curr Vasc Pharmacol. 2018;16(3):239-245. doi: 10.2174/1570161115666170621080835.
10
Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.非酒精性脂肪性肝病的生活方式干预:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Jun 11;6(6):CD013156. doi: 10.1002/14651858.CD013156.pub2.

本文引用的文献

1
Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease.建立和验证非酒精性脂肪性肝病生活方式干预依从性预测系统。
World J Gastroenterol. 2024 Mar 14;30(10):1393-1404. doi: 10.3748/wjg.v30.i10.1393.
2
Self-management behaviours in adults with non-alcoholic fatty liver disease: a cross-sectional survey from China.非酒精性脂肪性肝病成人的自我管理行为:来自中国的横断面调查。
BMJ Open. 2024 Feb 22;14(2):e078333. doi: 10.1136/bmjopen-2023-078333.
3
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
4
Global burden of liver disease: 2023 update.全球肝病负担:2023 年更新。
J Hepatol. 2023 Aug;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017. Epub 2023 Mar 27.
5
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease.美国肝病研究学会非酒精性脂肪性肝病临床评估与管理实践指南
Hepatology. 2023 May 1;77(5):1797-1835. doi: 10.1097/HEP.0000000000000323. Epub 2023 Mar 17.
6
Self-Management and Associated Factors among Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study.非酒精性脂肪性肝病患者的自我管理及相关因素:一项横断面研究。
Int J Environ Res Public Health. 2022 Dec 30;20(1):667. doi: 10.3390/ijerph20010667.
7
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.全球非酒精性脂肪性肝病的患病率和发病率:系统评价和荟萃分析。
Lancet Gastroenterol Hepatol. 2022 Sep;7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0. Epub 2022 Jul 5.
8
Non-alcoholic fatty liver disease: A patient guideline.非酒精性脂肪性肝病:患者指南。
JHEP Rep. 2021 Sep 17;3(5):100322. doi: 10.1016/j.jhepr.2021.100322. eCollection 2021 Oct.
9
Diet and exercise in NAFLD/NASH: Beyond the obvious.非酒精性脂肪性肝病/非酒精性脂肪性肝炎的饮食和运动:超越显而易见的。
Liver Int. 2021 Oct;41(10):2249-2268. doi: 10.1111/liv.15024. Epub 2021 Aug 21.
10
Development and initial validation of the nonalcoholic fatty liver disease self-management questionnaire.非酒精性脂肪性肝病自我管理问卷的制定和初步验证。
Res Nurs Health. 2021 Oct;44(5):844-853. doi: 10.1002/nur.22164. Epub 2021 Jun 13.

非酒精性脂肪性肝病患者自我管理的定量评估:未满足的临床需求。

Quantitative assessment of self-management in patients with non-alcoholic fatty liver disease: An unmet clinical need.

机构信息

CEMAD Digestive Disease Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of Rome, Rome 00168, Italy.

出版信息

World J Gastroenterol. 2024 Jul 7;30(25):3143-3146. doi: 10.3748/wjg.v30.i25.3143.

DOI:10.3748/wjg.v30.i25.3143
PMID:39006382
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11238672/
Abstract

In this editorial we comment on the article titled "Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease" by Zeng published in a recent issue of the . Non-alcoholic fatty liver disease (NAFLD) represents one of the current challenges in hepatology and public health, due to its continuous growing prevalence and the rising incidence of NAFLD-related fibrosis, non-alcoholic steatohepatitis and cirrhosis. The only effective therapeutic strategy for this disease is represented by encouraging patients to improve their lifestyle through the modification of dietary intake and increased physical exercise, but the effective application of such modifications is often limited by various factors such as lack of information, psychological barriers or poor social support. While poor adherence to a healthy lifestyle can be decisive in determining the clinical outcome, in daily practice there is a lack of quantitative instruments aimed at identifying patients with the lowest adherence to lifestyle changes and higher risk of disease progression in the course of follow-up. In this article, Zeng propose a quantitative scale to assess the grade of adherence of patients with NAFLD to healthy lifestyle intervention, called the Exercise and Diet Adherence Scale (EDAS). This scale, consisting of 33 items divided into 6 dimensions which relates to six subjective aspects in the self-management of NAFLD, has shown a good correlation with the identification of the sub-cohort of patients with the highest reduction in caloric intake, increase in physical exercise, probability of a reduction in liver stiffness measurement and alanine aminotransferase levels. The correlation among clinical outcomes and specific dimensions of this scale also highlights the pivotal role of a good and confidential doctor-patient relationship and of an effective communication. There is an urgent need for practical and effective instruments to assess the grade of self-management of NAFLD patients, together with the development of multidisciplinary teams with the aim of applying structured behavioral interventions.

摘要

在这篇社论中,我们对曾[1]发表在最近一期[2]上的题为“建立和验证非酒精性脂肪性肝病生活方式干预依从性预测系统”的文章进行了评论。非酒精性脂肪性肝病(NAFLD)是当前肝病学和公共卫生领域的挑战之一,因为其患病率持续增长,NAFLD 相关纤维化、非酒精性脂肪性肝炎和肝硬化的发病率也在上升。这种疾病唯一有效的治疗策略是通过改变饮食摄入和增加体育锻炼来鼓励患者改善生活方式,但这些改变的有效应用往往受到各种因素的限制,如缺乏信息、心理障碍或不良的社会支持。虽然不良的生活方式依从性可能对决定临床结果具有决定性作用,但在日常实践中,缺乏旨在识别对生活方式改变依从性最低、疾病进展风险最高的患者的定量工具。在这篇文章中,曾[1]提出了一种评估 NAFLD 患者对健康生活方式干预依从性的定量量表,称为运动和饮食依从性量表(EDAS)。该量表由 33 个项目组成,分为 6 个维度,与 NAFLD 自我管理的 6 个主观方面有关,与识别卡路里摄入减少最多、体力活动增加、肝硬度测量和丙氨酸氨基转移酶水平降低概率最高的患者亚组具有良好的相关性。该量表的临床结局与特定维度之间的相关性也突出了良好的医患关系和有效的沟通的关键作用。迫切需要实用有效的工具来评估 NAFLD 患者的自我管理程度,并建立多学科团队,以实施结构化的行为干预。